Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection.
In @TheLancetInfDis, authors summarise RSV preventive products, real-world effectiveness and uptake, and the opportunity of using communication in translating RSV prevention into impact: https://t.co/Jy80zuD9VO
European Respiratory Journal: Pulmonary fibrosis is driven by chronic inflammation that links immune dysregulation to fibroblast activation, paving the way for targeted, personalised therapeutic strategies https://t.co/7NrmJqKtsm
🫀Heart failure in 2026: we are no longer treating symptoms. We are redesigning the disease.
The latest evidence update reminds us of something profound:
Heart failure is no longer a single entity.
It is a spectrum, and now, finally, we are treating it as one.
Several paradigm shifts stand out.
1. SGLT2 inhibitors are no longer “add-on” therapy.
They are foundational across the entire EF spectrum.
From HFrEF to HFpEF, the data are now consistent.
Not just symptom improvement, but hard outcomes.
This may be the most important unifying therapy in modern HF.
2. HFpEF is no longer a therapeutic desert.
For the first time, we have real disease-modifying options:
Finerenone → outcome reduction across EF ranges
GLP-1 / dual incretin therapies → targeting the obesity phenotype
Structural and metabolic mechanisms are finally being addressed
We are moving from “HFpEF frustration” → HFpEF phenotyping.
3. Acute heart failure is no longer about stabilization.
It is about early transformation.
The new paradigm:
Start GDMT in-hospital
Optimize rapidly
Treat beyond congestion
Decongestion is still important, but it is no longer the goal.
Disease modification starts on day 1.
4. Decongestion is becoming precision medicine
Urine sodium-guided therapy
Early escalation of loop diuretics
Sequential nephron blockade
Not just “give furosemide”, but measure, adjust, and target response.
5. Devices are no longer rescue therapy, they are integrated care
TEER expanding from mitral → tricuspid
Pulmonary artery pressure monitoring reducing hospitalizations
Remote hemodynamics shaping outpatient management
The boundary between ICU, ward, and home is dissolving.
6. The biggest problem is no longer evidence.
It is implementation.
We already have:
Quadruple therapy
Proven outcome benefits
Yet many patients never reach target doses.
The gap is no longer science.
It is execution.
🤓Final message
Heart failure care has entered a new era:
Mechanism-based therapy
Early aggressive optimization
Phenotype-driven treatment
And perhaps most importantly:
We are no longer chasing symptoms.
We are altering the trajectory of the disease.
📃Reference
Liori S, et al. Heart failure evidence update 2026. Heart Failure Reviews. 2026. https://t.co/T4MVjK0vGd
💉🩺Rapid sequence intubation in 2026: we are no longer “protecting the airway.”
We are managing physiology under extreme stress.
The latest evidence challenges one of the oldest dogmas in critical care.
RSI was designed to prevent aspiration.
But today, the real enemy is often hypoxemia and cardiovascular collapse.
1. Aspiration is no longer the central problem
For decades, RSI was built around one fear: aspiration.
But emerging data suggest:
RSI may not significantly reduce aspiration
It may increase hypoxemia and hemodynamic instability
The paradigm is shifting:
👉 From aspiration avoidance → to physiologic optimization
2. First-pass success is everything
Every additional attempt increases:
Hypoxia
Hemodynamic collapse
Mortality
Modern RSI is built around one goal:
Get it right the first time.
That means:
Videolaryngoscopy first-line
Stylet routinely
Team choreography, not improvisation
3. Preoxygenation is now a therapeutic intervention
Not just a step—a determinant of survival
NIV > face mask
HFNO as adjunct
Semi-upright positioning
And one key shift:
👉 Gentle ventilation is no longer taboo
Done correctly, it reduces hypoxemia without increasing aspiration risk.
4. Hemodynamics matter more than ever
Up to 40–50% of patients experience peri-intubation instability.
The modern approach:
Avoid propofol in unstable patients
Favor etomidate or ketamine
Consider prophylactic vasopressors
Fluid loading?
Not routinely beneficial.
5. Cricoid pressure: from dogma to doubt
No clear benefit in preventing aspiration
May worsen laryngoscopy and ventilation
Current thinking:
👉 Use selectively, or not at all
6. RSI is no longer a rigid protocol
It is now:
Patient-specific
Physiology-driven
Team-dependent
With tools like:
Gastric ultrasound
POCUS-guided decisions
Structured airway protocols
7. The real determinant of success: human factors
Preparation, communication, and coordination matter as much as drugs.
Because in critical care:
The airway is not just anatomy.
It is a moment of systemic vulnerability.
🤓Final message
RSI has evolved:
From speed → to precision
From protocol → to physiology
From individual skill → to team performance
And ultimately:
The goal is no longer just to intubate.
It is to intubate without killing the patient.
📃Reference
Boulos NM et al. Anaesth Crit Care Pain Med. 2026. https://t.co/KWUfUtAMyP
Antiobesity drugs for the gastroenterologist 💡🆕
1️⃣ Tirzepatide (Mounjaro)
2️⃣ Action of GLP1s
3️⃣ Action of GIPs (glucose-dependent insulinotropic peptide)
4️⃣ Currently available GLP1s
📸: @lisa_shark@FrontGastro_BMJ
https://t.co/JVFlOC9O7t
📚📑 Iniciar anticoagulación de manera temprana o tardía en pacientes con #FA y ACV isquémico? Este estudio nos da respuestas a esta pregunta. 🏥📊
👇🏼👇🏼👇🏼👇🏼👇🏼
🔗🔑🔓
https://t.co/fHCFt7DbCO